On the recordJuly 27, 2021
Mr. Speaker, briefly, I think one of the things that is important to acknowledge is that to have such a broad and vague provision in what qualifies as promotion, it includes research and, one could argue, primarily affects scientific research to prevent us from actually having the evidence to assess these substances for what they are. Currently, much of the research that is being conducted right now is reliant on private funding, or the stigma and fear and the chilling effect associated with having these provisions on the books, which are largely unnecessary, prevents such critical research from being funded. Mr. Speaker, I yield 2 minutes to the gentleman from California (Mr. Correa), my colleague.





